15-Year watch begins for pioneering cancer cell therapy recipients
NCT ID NCT06976736
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 39 times
Summary
This long-term follow-up study tracks about 1,000 people who previously received an experimental T-cell therapy (TSC-100 or TSC-101) for blood cancers like AML, ALL, or MDS. Researchers will monitor participants for 15 years to check for any late side effects and to see how long they live without the cancer returning. The goal is to understand the lasting safety and effectiveness of this treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
Contact
Contact
-
Mount Sinai
RECRUITINGNew York, New York, 10029-6696, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.